Moreover, recent studies have discovered that when cells at tumor metastasis sites are in a dormant state, using STING agonists can inhibit cancer cells from progressing from a quiescent state to aggressive metastasis in a manner dependent on NK cells and T cells.228 Interestingly, the STING pathway undergoes dynamic changes in its expression levels—downregulation, upregulation, and then downregulation again—during the stages of dormancy, proliferation, and macrometastasis, mediated by epigenetic regulation. This evidence concerns the gene STING1 and neoplasm.